which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by Servier alongside IDH inhibitor stablemate Tibsovo (ivosidenib), which is already approved to ...

Alembic Pharmaceuticals on Thursday said it has received tentative approval from the US health regulator for its generic Ivosidenib tablets used in the treatment of certain types of cancer of bone ...